Welcome to Exocell
About Diabetes
About Our Products
Assay Kits
Reagents
New & Coming Soon
Scientific Support
About Our Services
Press Releases
Distributors
Ordering Info
Order Form
Contact Us

Glycated Albumin (Glycoalbumin)


Manufacturer/Trade: Exocell / Glycaben
Catalogue Numbers: Glycaben: 1003 Strip Plate
Methodology: Sandwich ELISA
Summary of procedure: Glycaben is an enzyme linked immunosorbent assay for the quantitative determination of glycoalbumin in human plasma. It provides information concerning glycemic control analogous to that offered by glycohemoglobin measurements, except that the protein measured is glycated albumin which has a shorter half-life.

The assay depends upon a monoclonal antibody, A717, that specifically recognizes the glycated moieties in glycated albumin. In practice, standards or samples are added to A717 coated plates (Glycaben). The glycoalbumin in these analytes binds to or is captured by the antibody on the solid phase, and unbound materials are washed away. A subsequent incubation with an enzyme conjugated antihuman albumin antibody leads to detection of the bound molecules. Bound conjugate is determined colorimetrically after reaction with a TMB substrate solution.

By relating sample response with that for the standards, the concentration of glycoalbumin may be determined. A separate analysis of total albumin allows the results to be converted to percent of total albumin that is glycated.

Specimen Required: 50ul citrate or EDTA treated plasma
Assay Range: 0.1-3 mg/ml glycated albumin
Sensitivity: 0.1 mg/ml
Precision: Intra- and interassay precision of samples within the assay range have a C.V. <10%.
Specificity: The monoclonal antibody A717 is specific for glycated albumin, and does not cross-react with other proteins that occur in human plasma including non-glycated albumin. The enzyme conjugated antibody preparation is specific for human albumin.
Expected Values: Plasma from normal non-diabetic individual have 0.4-2.4% glycated albumin whereas that from uncontrolled diabetics will be >2.5%.



© 2012 Exocell Inc.